1. Delmas, PD, Bjarnason, NH, Mitlak, BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337(23): 1641–1647.
Google Scholar | Crossref | Medline2. Sömjen, D, Waisman, A, Kaye, A. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo. J Steroid Biochem Mol Biol 1996; 59(5–6): 389–396.
Google Scholar | Crossref | Medline3. Black, LJ, Jones, CD, Falcone, JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen. Life Sci 1983; 32(9): 1031–1036.
Google Scholar | Crossref | Medline4. Gottardis, MM, Ricchio, ME, Satyaswaroop, PG, et al. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res 1990; 50(11): 3189–3192.
Google Scholar | Medline5. Kalidas, M, Hilsenbeck, S, Brown, P. Defining the role of raloxifene for the prevention of breast cancer. J Natl Cancer Inst 2004; 96(23): 1731–1733.
Google Scholar | Crossref | Medline6. Heringa, M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int J Clin Pharmacol Ther 2003; 41(8): 331–345.
Google Scholar | Crossref | Medline7. Boss, SM, Huster, WJ, Neild, JA, et al. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997; 177(6): 1458–1464.
Google Scholar | Crossref | Medline8. Jolly, EE, Bjarnason, NH, Neven, P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003; 10(4): 337–344.
Google Scholar | Crossref | Medline9. Hibner, M, Magrina, JF, Lefler, SR, et al. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecol Oncol 2004; 93(3): 642–646.
Google Scholar | Crossref | Medline10. Riggs, BL, Hartmann, LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice. N Engl J Med 2003; 348(7): 618–629.
Google Scholar | Crossref | Medline11. Rey, JRC, Cervino, EV, Rentero, ML, et al. Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice. Open Orthop J 2009; 3: 14.
Google Scholar | Crossref | Medline12. Chantalat, E, Valera, M-C, Vaysse, C, et al. Estrogen receptors and endometriosis. Int J Mol Sci 2020; 21(8): 2815.
Google Scholar | Crossref | Medline13. Fasciani, A, Bocci, G, Xu, J, et al. Three-dimensional in vitro culture of endometrial explants mimics the early stages of endometriosis. Fertil Steril 2003; 80(5): 1137–1143.
Google Scholar | Crossref | Medline14. Khazaei, M, Montaseri, A, Casper, RF. Letrozole stimulates the growth of human endometrial explants cultured in three-dimensional fibrin matrix. Fertil Steril 2009; 91(5): 2172–2176.
Google Scholar | Crossref | Medline15. Rezavand, N, Khazaei, M, Oliapanah, E, et al. Low doses of celecoxib stimulate human endometrium growth in a three-dimensional culture model. Int J Fertil Steril 2013; 7(1): 7.
Google Scholar | Medline16. Khazaei, MR, Nasr-Esfahani, MH, Chobsaz, F, et al. Noscapine inhibiting the growth and angiogenesis of human eutopic endometrium of endometriosis patients through expression of apoptotic genes and nitric oxide reduction in three-dimensional culture model. Iran J Pharm Res 2019; 18(2): 836.
Google Scholar | Medline17. Huster, W, Boss, S, Glant, M, et al. Raloxifene does not cause endometrial proliferation in postmenopausal women. J Soc Gynecol Investig 1996; 2(3): 142A.
Google Scholar18. Katzenellenbogen, BS, Katzenellenbogen, JA. Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000; 2(5): 335.
Google Scholar | Crossref | Medline19. Seeman, E. Raloxifene. J Bone Miner Metab 2001; 19(2): 65–75.
Google Scholar | Crossref | Medline20. Pettersson, K, Delaunay, F, Gustafsson, J-Å. Estrogen receptor [beta] acts as a dominant regulator of estrogen signaling. Oncogene 2000; 19(43): 4970.
Google Scholar | Crossref | Medline21. Bläuer, M, Heinonen, PK, Rovio, P, et al. Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model. Eur J Pharmacol 2008; 592(1): 13–18.
Google Scholar | Crossref | Medline22. Morishima, S, Shibata, M-A, Ohmichi, M, et al. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells. Med Mol Morphol 2008; 41(3): 132–138.
Google Scholar | Crossref | Medline23. Liu, J, Matsuo, H, Xu, Q, et al. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod 2007; 22(5): 1253–1259.
Google Scholar | Crossref | Medline24. Draper, MW, Flowers, DE, Huster, WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11(6): 835–842.
Google Scholar | Crossref | Medline25. Yao, Z, Shen, X, Capodanno, I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Investig Surg 2005; 18(4): 177–183.
Google Scholar | Crossref | Medline